RS59678B1 - Derivati 8-hidroksi-hinolina - Google Patents

Derivati 8-hidroksi-hinolina

Info

Publication number
RS59678B1
RS59678B1 RS20191622A RSP20191622A RS59678B1 RS 59678 B1 RS59678 B1 RS 59678B1 RS 20191622 A RS20191622 A RS 20191622A RS P20191622 A RSP20191622 A RS P20191622A RS 59678 B1 RS59678 B1 RS 59678B1
Authority
RS
Serbia
Prior art keywords
group
groups
methyl
branched
carbon atoms
Prior art date
Application number
RS20191622A
Other languages
English (en)
Serbian (sr)
Inventor
László Puskás
Csaba Szabó
Iván KANIZSAI
Márió GYURIS
Ramóna MADÁCSI
Béla ÓZSVÁRI
Liliána FEHÉR
Gábor Tamás
Original Assignee
Avidin Kutato Fejlesztoe Es Kereskedelmi Korlatolt Feleloessegue Tarsasag
Soneas Kutato Korlatolt Felelossegu Tarsasag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avidin Kutato Fejlesztoe Es Kereskedelmi Korlatolt Feleloessegue Tarsasag, Soneas Kutato Korlatolt Felelossegu Tarsasag filed Critical Avidin Kutato Fejlesztoe Es Kereskedelmi Korlatolt Feleloessegue Tarsasag
Publication of RS59678B1 publication Critical patent/RS59678B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
RS20191622A 2010-05-06 2011-05-06 Derivati 8-hidroksi-hinolina RS59678B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU1000243A HUP1000243A2 (en) 2010-05-06 2010-05-06 8-hidroxy-quinoline derivatives
PCT/HU2011/000043 WO2011148208A1 (en) 2010-05-06 2011-05-06 8-hydroxy-quinoline derivatives
EP11752335.7A EP2566849B1 (en) 2010-05-06 2011-05-06 8-hydroxy-quinoline derivatives

Publications (1)

Publication Number Publication Date
RS59678B1 true RS59678B1 (sr) 2020-01-31

Family

ID=89989711

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20191622A RS59678B1 (sr) 2010-05-06 2011-05-06 Derivati 8-hidroksi-hinolina

Country Status (21)

Country Link
US (1) US8871937B2 (OSRAM)
EP (1) EP2566849B1 (OSRAM)
JP (1) JP5812541B2 (OSRAM)
KR (1) KR101837974B1 (OSRAM)
CN (1) CN102985407B (OSRAM)
AU (1) AU2011256989B2 (OSRAM)
CA (1) CA2798419C (OSRAM)
CY (1) CY1122426T1 (OSRAM)
DK (1) DK2566849T3 (OSRAM)
EA (1) EA021026B1 (OSRAM)
ES (1) ES2761832T3 (OSRAM)
HR (1) HRP20192278T1 (OSRAM)
HU (2) HUP1000243A2 (OSRAM)
MX (1) MX337999B (OSRAM)
NZ (1) NZ603967A (OSRAM)
PL (1) PL2566849T3 (OSRAM)
PT (1) PT2566849T (OSRAM)
RS (1) RS59678B1 (OSRAM)
SI (1) SI2566849T1 (OSRAM)
SM (1) SMT201900710T1 (OSRAM)
WO (1) WO2011148208A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP1500098A2 (hu) * 2015-03-09 2016-09-28 Avidin Kft 8-hidroxikinolin származékok új enantiomerjei és szintézisük
US10624881B2 (en) * 2015-10-12 2020-04-21 Health Research, Inc. Methods for inducing apoptosis in cancer cells
CN105367553A (zh) * 2015-12-04 2016-03-02 广东工业大学 一种他克林-8-羟（胺）基喹啉衍生物及其应用
HUP1600234A2 (en) 2016-04-05 2017-12-28 Mta Termeszettudomanyi Kutatokoezpont Mdr-reversing 8-hydroxy-quinoline derivatives
WO2024073624A2 (en) * 2022-09-28 2024-04-04 The Research Foundation For The State University Of New York Antiproliferative betti bases and prodrugs thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544972B1 (en) 1997-09-25 2003-04-08 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
CA2319131A1 (en) 1998-01-26 1999-07-29 Walter H. Moos Mitochondria protecting agents for treating mitochondria associated diseases
US6737511B1 (en) 1999-08-16 2004-05-18 The United States Of America As Represented By The Department Of Health And Human Services Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
BR0013666A (pt) 1999-08-27 2002-05-14 Cytovia Inc "alfa"-hidróxi-ácidos substituìdos inibidores de caspases e o seu uso
US6890896B1 (en) 1999-11-18 2005-05-10 Ceremedix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
US6476048B1 (en) 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
US6531464B1 (en) 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
US6534651B2 (en) 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
GB0011095D0 (en) 2000-05-08 2000-06-28 Black James Foundation astrin and cholecystokinin receptor ligands (III)
WO2002030411A2 (en) 2000-10-13 2002-04-18 Johns Hopkins University Treatment of apoptotic cell death
US6552076B2 (en) 2000-12-15 2003-04-22 Mitokor Compounds for altering mitochondrial function and cellular responses
US7601846B2 (en) 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
DE60233738D1 (de) 2001-07-10 2009-10-29 Biogen Idec Inc Hemmung des apoptoseprozesses und verbesserung der zelleistung
DE10144153A1 (de) 2001-09-07 2003-03-27 Newfrey Llc Halteclip mit versetzten Rastfingern
CA2475963A1 (en) 2002-02-13 2003-09-04 Beth Israel Deaconess Medical Center, Inc. Methods of treating vascular disease
AU2004258801A1 (en) 2003-02-28 2005-02-03 Inotek Pharmaceuticals Corporation Tetracyclic Benzamide Derivatives and methods of use thereof
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
AU2004242947B2 (en) 2003-05-28 2010-04-29 Eisai Inc. Compounds, methods and pharmaceutical compositions for inhibiting PARP
CA2851972C (en) 2004-01-23 2015-06-23 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
EP1966157B1 (en) 2005-11-15 2010-03-24 Abbott Laboratories Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
US7528174B2 (en) 2006-01-06 2009-05-05 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Selective targeting agents for mitochondria
WO2008014602A1 (en) * 2006-07-25 2008-02-07 Envivo Pharmaceuticals, Inc. Quinoline derivatives
EP3085367A3 (en) * 2007-03-20 2017-01-25 Brandeis University Compositions for the diagnosis, treatment, and prevention of amyotrophic lateral sclerosis and related
US8183236B2 (en) * 2007-04-12 2012-05-22 University Of Southern California Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics
JP2010530736A (ja) 2007-05-25 2010-09-16 バーンハム インスティトゥート フォー メディカル リサーチ タプシガルジンにより誘導される細胞死の阻害剤
US8138356B2 (en) * 2007-10-16 2012-03-20 Angiogeney, Inc. Chemical inhibitors of inhibitors of differentiation
WO2009151972A1 (en) * 2008-05-28 2009-12-17 , The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of U.S. Army Medical Research And Materiel Command Small molecule inhibitors of botulinum neurotoxins
US8658170B2 (en) * 2010-01-06 2014-02-25 Joseph P. Errico Combination therapy with MDM2 and EFGR inhibitors
CA2786289A1 (en) * 2010-01-06 2011-07-14 Joseph P. Errico Methods and compositions of targeted drug development

Also Published As

Publication number Publication date
PL2566849T3 (pl) 2020-03-31
EP2566849A1 (en) 2013-03-13
SMT201900710T1 (it) 2020-01-14
US20130131096A1 (en) 2013-05-23
CN102985407A (zh) 2013-03-20
NZ603967A (en) 2014-06-27
EA201270787A1 (ru) 2013-04-30
KR20130029772A (ko) 2013-03-25
AU2011256989A1 (en) 2013-01-10
HUP1000243A2 (en) 2012-01-30
CA2798419C (en) 2021-01-05
JP2013525473A (ja) 2013-06-20
US8871937B2 (en) 2014-10-28
KR101837974B1 (ko) 2018-03-13
CY1122426T1 (el) 2021-01-27
AU2011256989B2 (en) 2014-08-21
WO2011148208A1 (en) 2011-12-01
CA2798419A1 (en) 2011-12-01
HUE050886T2 (hu) 2021-01-28
JP5812541B2 (ja) 2015-11-17
ES2761832T3 (es) 2020-05-21
MX337999B (es) 2016-03-30
PT2566849T (pt) 2020-01-06
HU1000243D0 (en) 2010-06-28
DK2566849T3 (da) 2020-01-02
SI2566849T1 (sl) 2020-02-28
EA021026B1 (ru) 2015-03-31
EP2566849B1 (en) 2019-09-18
CN102985407B (zh) 2015-09-09
HRP20192278T1 (hr) 2020-03-06
MX2012012883A (es) 2013-03-20

Similar Documents

Publication Publication Date Title
Thakkar et al. Benzothiazole analogues: Synthesis, characterization, MO calculations with PM6 and DFT, in silico studies and in vitro antimalarial as DHFR inhibitors and antimicrobial activities
US20180134684A1 (en) Methods to induce targeted protein degradation through bifunctional molecules
US8513433B2 (en) Small molecule inhibitors of PARP activity
JP4722851B2 (ja) キノリンカリウムチャネル阻害剤
BG65047B1 (bg) Заместени бензимидазоли и тяхното използване катоparp инхибитори
RS59678B1 (sr) Derivati 8-hidroksi-hinolina
WO2016148114A1 (ja) 酸化ストレス誘導神経細胞死抑制化合物
KR20160003196A (ko) ＂니코틴아미드 포스포리보실트랜스퍼라제의 억제제, 조성물, 제품 및 그의 용도＂
CN116891463A (zh) 作为at2r激动剂的杂环化合物
Qiu et al. Discovery of novel harmine derivatives as GSK‐3β/DYRK1A dual inhibitors for Alzheimer's disease treatment
CN107857760A (zh) 鞘氨醇‑1‑磷酸受体调节剂及其应用
JP4794445B2 (ja) キノリンカリウムチャネル阻害剤
EP2880034B1 (en) Amino-heteroaryl 7-hydroxy-spiropiperidine indolinyl antagonists of p2y1 receptor
KR102333863B1 (ko) 신규한 피라졸 유도체
AU2017341020B2 (en) Urea derivative
KR101394534B1 (ko) 신규한 １ｈ-인다졸-５-일아미노-치환 헤테로사이클릭 화합물 및 이를 포함하는 약제학적 조성물
CA3093551A1 (en) Compounds for treatment of cardiac arrhythmias and heart failure
CN107383002A (zh) 一类含氟三氮唑并吡啶类化合物及其制备方法、药物组合物和用途
US9381260B2 (en) Hypoxia inducible factor-1 pathway inhibitors and uses as anticancer and imaging agents
JP2001302669A (ja) 三環性フタラジノン誘導体
CN112823006B (zh) 用作神经保护剂的醌还原酶2抑制剂
CN113956249B (zh) 脑靶向AChE抑制剂前药及其制备方法与应用
KR20080053950A (ko) 오르토 치환 아닐린 유도체 및 항산화약
CN120051457A (zh) 草酸酰胺化合物、包含其的药物组合物及其制备方法和用途